Opioid induced nausea and vomiting

European Journal of Pharmacology

Volumn 722, Issue 1, 2014, Pages 67-78

  Smith, Howard S ^a   Laufer, Andras ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Antagonists; Moxduo; Nausea; NK 1; Olanzapine; Opioids; Tapentadol; Vomiting

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDROMORPHONE; IODOBENZOYLNALTREXAMIDE; METOCLOPRAMIDE; MORPHINE; MORPHINE PLUS OXYCODONE; MOXDUO; MU OPIATE RECEPTOR; NALOXONE PLUS OXYCODONE; NALTREXONE PLUS OXYCODONE; NARCOTIC ANALGESIC AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; OXYCODONE; OXYMORPHONE; PALONOSETRON; PIRITRAMIDE; PLACEBO; PRUCALOPRIDE; RISPERIDONE; SEROTONIN; TAPENTADOL; UNCLASSIFIED DRUG;

AREA POSTREMA; BEDTIME DOSAGE; CANCER PAIN; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; CONSTIPATION; DRUG DOSE TITRATION; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART ARREST; HEART DISEASE; HETEROZYGOTE; HUMAN; INTESTINE FUNCTION DISORDER; LOW BACK PAIN; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OPIOID INDUCED NAUSEA AND VOMITING; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PATIENT CONTROLLED ANALGESIA; PHARMACOGENETICS; POSTOPERATIVE ILEUS; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SOLITARY TRACT NUCLEUS; UNSPECIFIED SIDE EFFECT; VAGUS NERVE DORSAL NUCLEUS; VOMITING;

ANTAGONISTS; MOXDUO; NAUSEA; NK-1; OLANZAPINE; OPIOIDS; TAPENTADOL; VOMITING;

ANALGESICS, OPIOID; ANIMALS; ANTIEMETICS; HUMANS; NAUSEA; NEUROTRANSMITTER AGENTS; PHARMACOGENETICS; VOMITING;

EID: 84892991311     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.09.074     Document Type: Review

References (168)

1. M. Afilalo, M.S. Etropolski, B. Kuperwasser, K. Kelly, A. Okamoto, I. Van Hove, A. Steup, B. Lange, C. Rauschkolb, and J. Haeussler Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study Clin. Drug Investig. 30 2010 489 505
2. M. Ali, D.C. Winter, A.M. Hanly, C. O'Hagan, J. Keaveny, and P. Broe Prospective, randomized, controlled trial of thoracic epidural or patient-controlled opiate analgesia on perioperative quality of life Br. J. Anaesth. 104 2010 292 297
3. C.C. Apfel, and S. Jukar-Rao Is palonosetron also effective for opioid-induced and post-discharge nausea and vomiting? Br. J. Anaesth. 108 2012 371 373
4. C.C. Apfel, E. Laara, M. Koivuranta, C.A. Greim, and N. Roewer A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers Anesthesiology 91 1999 693 700
5. C.C. Apfel, P. Kranke, M.H. Katz, C. Goepfert, T. Papenfuss, S. Rauch, R. Heineck, C.A. Greim, and N. Roewer Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design Br. J. Anaesth. 88 2002 659 668
6. C.C. Apfel, K. Korttila, M. Abdalla, H. Kerger, A. Turan, I. Vedder, C. Zernak, K. Danner, R. Jokela, S.J. Pocock, S. Trenkler, M. Kredel, A. Biedler, D.I. Sessler, N. Roewer, and IMPACT Investigators A factorial trial of six interventions for the prevention of postoperative nausea and vomiting N. Engl. J. Med. 350 2004 2441 2451
7. R.H. Arends, T.G. Hayashi, T.J. Luger, and D.D. Shen Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats J. Pharmacol. Exp. Ther. 286 1998 585 592
8. M.L. Aylwin, J.M. Horowitz, and A.C. Bonham Non-NMDA and NMDA receptors in the synaptic pathway between area postrema and nucleus tractus solitarius Am. J. Physiol. 275 1998 H1236 1246
9. D.T. Baptista-Hon, and Z.T. Deeb The 5-HT3B subunit affects high-potency inhibition of 5-HT3 receptors by morphine Br. J. Pharmacol. 165 2012 693 704
10. D. Bagnol, A. Mansour, H. Akil, and S.J. Watson Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract Neuroscience 81 1997 579 591
11. G. Bentsen, and A. Stubhaug Cardiac arrest after intravenous metoclopramide: a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest Acta Anaesthesiol. Scand. 46 2002 908 910
12. J.P. Blancquaert, R.A. Lefebvre, and J.L. Willems Emetic and antiemetic effects of opioids in the dog Eur. J. Pharmacol. 128 1986 143 150
13. T.A. Bowdle Adverse effects of opioid agonists and agonist-antagonists in anesthesia Drug Saf. 19 1998 173 189
14. C. Breitfeld, J. Peters, T. Vockel, C. Lorenz, and M. Eikermann Emetic effects of morphine and piritramide Br. J. Anaesth. 91 2003 218 223
15. K.N. Browning, and R.A. Travagli Characterization of the in vitro effects of 5-hydroxytryptamine (5-HT) on identified neurones of the rat dorsal motor nucleus of the vagus (DMV) Br. J. Pharmacol. 128 1999 1307 1315
16. R. Buynak, D.Y. Shapiro, A. Okamoto, I. Van Hove, C. Rauschkolb, A. Steup, B. Lange, C. Lange, and M. Etropolski Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study Expert Opin. Pharmacother. 11 2010 1787 1804
17. K.A. Candiotti, A.L. Kovac, T.I. Melson, G. Clerici, and T. Joo Gan A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting Anesth. Analg. 107 2008 445 451
18. P.A. Cantarella, and L.A. Chahl Acute effects of morphine on substance P concentrations in microdissected regions of guinea-pig brain Behav. Pharmacol. 7 1996 470 476
19. Y. Chen, C. Geis, and C. Sommer Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway J. Neurosci. 28 2008 5836 5845
20. F. Chung, R. Lane, C. Spraggs, B. McQuade, M. Jacka, H.H. Luttropp, S. Alahuta, S. Rocherieux, M. Roy, P. Duvaldestin, and P. Curtis Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients Eur. J. Anaesthesiol. 16 1999 669 677
21. R.M. Cole, F. Robinson, L. Harvey, K. Trethowan, and V. Murdoch Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer J. Pain Symptom Manage. 9 1994 48 50
22. F. Coluzzi, and M. Pappagallo Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy Minerva Anestesiol. 71 2005 425 433
23. F. Coluzzi, A. Rocco, I. Mandatori, and C. Mattia Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation Curr. Pharm. Des. 18 2012 1 10
24. M. Comelon, K. Wisloeff-Aese, J. Raeder, T. Draegni, H. Undersrud, E. Qvigstad, C.E. Bjerkelund, and H. Lenz A comparison of oxycodone prolonged-release vs. oxycodone+ naloxone prolonged-release after laparoscopic hysterectomy Acta Anaesthesiol. Scand. 57 2013 509 517
25. D.J. Costello, and H.L. Borison Naloxone antagonizes narcotic self blockade of emesis in the cat J. Pharmacol. Exp. Ther. 203 1977 222 230
26. L. Coulbault, M. Beaussier, C. Verstuyft, H. Weickmans, L. Dubert, D. Trégouet, C. Descot, Y. Parc, A. Lienhart, P. Jaillon, and L. Becquemont Environmental and genetic factors associated with morphine response in the postoperative period Clin. Pharmacol. Ther. 79 2006 316 324
27. S.E. Daniels, D. Upmalis, A. Okamoto, C. Lange, and J. Häeussler A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain Curr. Med. Res. Opin. 25 2009 765 776
28. M.P. Davis The opioid bowel syndrome: a review of pathophysiology and treatment J. Opioid Manag. 1 2005 153 161
29. M.P. Davis, G. Hallerberg, and Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation J. Pain Symptom Manage. 39 2010 756 767
30. M. Davis, H.W. Goforth, and P. Gamier Oxycodone combined with opioid receptor antagonists: efficacy and safety Expert Opin. Drug Saf. 12 2013 389 402
31. G.E. DeLander, H.I. Mosberg, and F. Porreca Involvement of adenosine in antinociception produced by spinal or supraspinal receptor-selective opioid agonists: dissociation from gastrointestinal effects in mice J. Pharmacol. Exp. Ther. 263 1992 1097 1104
32. P. Diemunsch, and L. Grélot Potential of substance P antagonists as antiemetics Drugs 60 2000 533 546
33. M.F. Divin, M.C. Holden Ko, and J.R. Traynor Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine dependent mice Eur. J. Pharmacol. 583 2008 48 55
34. A.V. Emmanuel, M.A. Kamm, A.J. Roy, R. Kerstens, and L. Vandeplassche Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n=1 study Aliment. Pharmacol. Ther. 35 2012 48 55
35. M.S. Etropolski, A. Okamoto, D.Y. Shapiro, and C. Rauschkolb Dose conversion between tapentadol immediate and extended release for low back pain Pain Physician 13 2010 61 70
36. F.D. Ferris, I.G. Kerr, M. Sone, and M. Marcuzzi Transdermal scopolamine use in the control of narcotic-induced nausea J. Pain Symptom Manage. 6 1991 380 393
37. E. Fukushi, M. Saito, H. Sato, T. Endo, N. Hamaue, M. Hirafuji, M. Minami, and Y. Kang Functional roles of 5-hydroxytryptamine 3/4 receptors in neurons of rat dorsal motor nucleus of the vagus Neuroscience 141 2006 675 685
38. T.J. Gan, T.A. Meyer, C.C. Apfel, F. Chung, P.J. Davis, A.S. Habib, V.D. Hooper, A.L. Kovac, P. Kranke, P. Myles, B.K. Philip, G. Samsa, D.I. Sessler, J. Temo, M.R. Tramèr, C. Vander Kolk, M. Watcha, and Society for Ambulatory Anesthesia Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting Anesth. Analg. 105 2007 1615 1628
39. E. George, C. Hornuss, and C.C. Apfel Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting Curr. Opin. Anaesthesiol. 23 2010 714 721
40. R.J. Gralla, L.M. Itri, S.E. Pisko, A.E. Squillante, D.P. Kelsen, D.W. Braun Jr., L.A. Bordin, T.J. Braun, and C.W. Young Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N. Engl. J. Med. 305 1981 905 909
41. Y.K. Gupta, P. Bhandari, A. Chuph, S.D. Seth, K.S. Dixit, and K.P. Bhargava Role of endogenous opioids and histamine in morphine induced emesis Indian J. Exp. Biol. 27 1989 52 54
42. A.S. Habib, and T.J. Gan The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia J. Clin. Anesth. 20 2008 35 39
43. M. Hale, D. Upmalis, A. Okamoto, C. Lange, and C. Rauschkolb Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study Curr. Med. Res. Opin. 25 2009 1095 1104
44. S.N. Harris, F.B. Sevarina, R.S. Sinatra, L. Preble, T.Z. O'Connor, and D.G. Silverman Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia Obstet. Gynecol. 78 1991 673 677
45. C. Hartrick, I. Van Hove, J. Stegmann, C. Oh, and D. Upmalis Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study Clin. Ther. 31 2009 260 271
46. I. Henzi, B. Walder, and M.R. Tramer Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies Br. J. Anaesth. 83 1999 761 771
47. M.A. Herman, A. Alayan, N. Sahibzada, B. Bayer, J. Verbalis, K.L. Dretchem, and R.A. Gillis micro-Opioid receptor stimulation in the medial subnucleus of the tractus solitaries inhibits gastric tone and motility by reducing local GABA activity Am. J. Physiol. Gastrointest. Liver Physiol. 299 2010 G494 506
48. C.M. Herndon, K.C. Jackson 2nd, and P.A. Hallin Management of opioid induced gastrointestinal effects in patients receiving palliative care Pharmacotherapy 22 2002 240 250
49. J. Hersom, and J.E. MacKenzie Opioid receptors involved in emesis in the dog Br. J. Pharmacol. 92 1987 648P
50. J.R. Holtman Jr. Immunohistochemical localization of serotonin- and substance P-containing fibers around respiratory muscle motoneurons in the nucleus ambiguus of the cat Neuroscience 26 1988 169 178
51. D. Hong, P. Flood, and G. Diaz The side effects of morphine and hydromorphone patient-controlled analgesia Anesth. Analg. 107 2008 1384 1389
52. P.J. Hornby Central neurocircuitry associated with emesis Am. J. Med. 111 2001 106S 112S
53. V.V. Iasnetsov, IuV. Drozd, and V.S. Shashkov Emetic and antiemetic properties of regulatory peptides Biull. Eksp. Biol. Med. 103 1987 586 588
54. M. Ishihara, H. Ikesue, H. Matsunaga, K. Suemaru, K. Kitaichi, K. Suetsugu, R. Oishi, T. Sendo, H. Araki, Y. Itoh, and Japanese Study Group for the Relief of opioids-induced Gastrointestinal Dysfuntion A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction Clin. J. Pain 28 2012 373 381
55. W.C. Jackson, and L. Tavernier Olanzapine for intractable nausea in palliative care patients J. Palliat. Med. 6 2003 251 255
56. S. Jakobovits, M. Mcdonough, and R.Y. Chen Buprenorphine-associated gastroparesis during in-patient heroin detoxification Addiction 101 2007 490 491
57. P. Janssen, H. Pottel, R. Vos, and J. Tack Endogenously released opioids mediate meal-induced gastric relaxation via peripheral mu-opioid receptors Aliment. Pharmacol. Ther. 33 2011 607 614
58. I.D. Jeong, M. Camilleri, A. Shin, J. Iturrino, A. Boldingh, I. Busciglio, D. Burton, M. Ryks, D. Rhoten, and A.R. Zinsmeister A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans Aliment. Pharmacol. Ther 2013 (in press) http://dx.doi.org/10.1111/j.1365-2036.2012.05040.x
59. R.R. Ji, R.W.T. Gereau, M. Malcangio, and G.R. Strichartz MAP kinase and pain Brain Res. Rev. 60 2009 135 148
60. T. Jolas, and G.K. Aghajanian Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro Brain Res. 755 1997 229 245
61. T. Jolas, E.J. Nestler, and G.K. Aghajanian Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway Neurosciences 95 2000 433 443
62. N. Jongkamonwiwat, P. Phansuwan-Pujito, P. Sarapoke, B. Chetsawang, S.O. Casalotti, A. Forge, H. Dodson, and P. Govitrapong The presence of opioid receptors in rat inner ear Hear. Res. 181 2003 85 93
63. E. Kalso, J.E. Edwards, R.A. Moore, and H.J. McQuay Opioids in chronic noncancer pain: systematic review of efficacy and safety Pain 112 2004 372 380
64. G.N.C. Kenny, J.D.L. Oates, J. Leeser, D.J. Rowbotham, H. Lip, M. Rust, P. Saur, M. Onsrud, and C.G. Haigh Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study Br. J. Anaesth. 68 1992 466 470
65. E. Kim, C.B. Choi, C. Kang, and S.C. Bae Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants Ann. Rheum. Dis. 69 2010 1889 1890
66. Y.Y. Kim, S.Y. Moon, D.U. Song, K.H. Lee, J.W. Song, and Y.E. Kwon Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery Korean J. Anesthesiol. 64 2013 122 126
67. A.C. King, J.R. Volpicelli, M. Gunduz, C.P. O'Brien, and M.J. Kreek Naltrexone biotransformation and incidence of subjective side effects: a preliminary study Alcohol. Clin. Exp. Res. 21 1997 906 909
68. P. Klepstad, T. Fladvad, F. Skorpen, K. Bjordal, A. Caraceni, O. Dale, A. Davies, M. Kloke, S. Lundström, M. Maltoni, L. Radbruch, R. Sabatowski, V. Sigurdardottir., F. Strasser, P.M. Fayers, S. Kaasa, and European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care Research Network Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients Pain 152 2011 1139 1145
69. A.P. Knox, N.L. Strominger, A.H. Battles, and D.O. Carpenter Behavioral studies of emetic sensitivity in the ferret Brain Res. Bull. 31 1993 477 484
70. Y. Kolesnikov, B. Gabovits, A. Levin, E. Voiko, and A. Veske Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects Anesth. Analg. 112 2011 448 453
71. Y.A. Kolesnikov, C.G. Pick, G. Ciszewska, and G.W. Pasternak Blockade of tolerance to morphine but not to κ opioids by a nitric oxide synthase inhibitor Proc. Natl. Acad. Sci. USA 90 1993 5162 5166
72. D.M. Kotelko, R.L. Rottman, W.C. Wright, J.J. Stone, A.Y. Yamashiro, and R.M. Rosenblatt Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine Anesthesiology 71 1989 675 678
73. A.L. Kovac, L. Eberhart, J. Kotarski, G. Clerici, and C. Apfel A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period Anesth. Analg. 107 2008 439 444
74. R.E. Kraichely, A.S. Arora, and J.A. Murray Opiate-induced oesophageal dysmotility Aliment. Pharmacol. Ther. 31 2010 601 606
75. B. Lange, B. Kuperwasser, A. Okamoto, A. Steup, T. Häufel, J. Ashworth, and M. Etropolski Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain Adv. Ther. 27 2010 381 399
76. E.A. Laugsand, T. Fladvad, F. Skorpen, M. Maltoni, S. Kaasa, P. Fayers, and P. Klepstad Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids Eur. J. Cancer 47 2011 1682 1691
77. K.A. Lehmann Opioids: overview on action, interaction and toxicity Support. Care Cancer 5 1997 439 444
78. Z. Li, J. Ichikawa, J. Dai, and H.Y. Meltzer Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur. J. Pharmacol. 16 2004 75 83
79. B. Lind, and H. Breivik Metoclopramide and perphenazine in the prevention of postoperative nausea and vomiting Br. J. Anaesth. 42 1970 614 617
80. K.A. Loper, L.B. Ready, and B.H. Dorman Prophylactic transdermal scopolamine patches reduce nausea in postoperative patients receiving epidural morphine Anesth. Analg. 68 1989 144 146
81. W. Ma, W.-H. Zheng, K. Powell, K. Jhamandas, and R. Quirion Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study Eur. J. Neurosci. 14 2001 1091 1104
82. S. Majumdar, M. Burgman, N. Haselton, S. Grinnell, J. Ocampo, A.R. Pasternak, and G.W. Pasternak Generation of novel radiolabeled opiates through site-selective iodination Bioorg. Med. Chem. Lett. 21 2011 4001 4004
83. S. Majumdar, S. Grinnell, V. Le Rouzic, M. Burgman, L. Polikar, M. Ansonoff, J. Pintar, Y.X. Pan, and G.W. Pasternak Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects Proc. Natl. Acad. Sci. USA 108 2011 19778 19783
84. A. Mansour, C.A. Fox, S. Burke, H. Akil, and S.J. Watson Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS J. Chem. Neuroanat. 8 1995 283 305
85. S. Martin-Schild, A.A. Gerall, A.J. Kastin, and J.E. Zadina Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent J. Comp. Neurol. 405 1999 450 471
86. S. McLean, A. Ganong, P.A. Seymour, D.K. Bryce, R.T. Crawford, J. Morrone, L.S. Reynolds, A.W. Schmidt, S. Zorn, J. Watson, A. Fossa, M. DePasquale, T. Rosen, A. Nagahisa, M. Tsuchiya, and J. Heym Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor J. Pharmacol. Exp. Ther. 277 1996 900 908
87. S. Mehendale, and C.S. Yuan Opioid-induced gastrointestinal dysfunction Dig. Dis. 24 2006 105 112
88. M.C. Meyer, A.B. Straughn, M.W. Lo, W.L. Schary, and C.C. Whitney Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration J. Clin. Psychiatry 45 1984 15 19
89. R.S.W. Middleton The use of metoclopramide in the elderly Postgrad. Med. J. 49 1973 90 93
90. A.D. Miller, and R.A. Leslie The area postrema and vomiting Front. Neuroendocrinol. 15 1994 301 320
91. F. Mitchelson Pharmacological agents affecting emesis, a review (part I) Drugs 43 1992 295 315
92. Y.E. Moon, J. Joo, J.E. Kim, and Y. Lee Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study Br. J. Anaesth. 108 2012 417 422
93. R.A. Moore, and H.J. McQuay Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Arthritis Res. Ther. 7 2005 R1046 1051
94. K. Munstedt, H. Muller, E. Blauth-Eckmeyer, K. Stenger, M. Zygmunt, and H. Vahrson Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting Br. J. Cancer 79 1999 637 639
95. M. Narita, M. Ioka, M. Suzuki, and T. Suzuki Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain Neurosci. Lett. 324 2002 97 100
96. R.M. Navari, L.H. Einhorn, S.D. Passik, P.J. Loehrer Sr., C. Johnson, M.L. Mayer, J. McClean, J. Vinson, and W. Pletcher A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study Support. Care Cancer 13 2005 529 534
97. R.M. Navari, L.H. Einhorn, P.J. Loehrer, S.D. Passik, J. Vinson, J. McClean, N. Chowhan, N.H. Hanna, and C.S. Johnson A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study Support. Care Cancer 15 2007 1285 1291
98. Y. Okamoto, S. Tsuneto, Y. Matsuda, T. Inoue, H. Tanimukai, K. Tazumi, Y. Ono, N. Kurokawa, and E. Uejima A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients J. Pain Symptom Manage. 34 2007 217 222
99. R.J. Osbourne, M.L. Slevin, S.P. Joel, D.M. Trew, P.I. Thompson, and J.S. Malpas The analgesic activity and pharmacokinetics of morphine-6-glucuronide in man Br. J. Cancer 60 1989 451
100. B. Otto, R.L. Riepl, S. Klosterhalfen, and P. Enck Endocrine correlates of acute nausea and vomiting Auton. Neurosci. 129 2006 17 21
101. S.J. Panchal, P. Muller-Schwefe, and J.I. Wurzelmann Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden Int. J. Clin. Pract. 61 2007 1181 1187
102. S.K. Park, and E.J. Cho A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery J. Int. Med. Res. 39 2011 399 407
103. S.D. Passik, J. Lundberg, K.L. Kirsh, D. Theobald, K. Donaghy, E. Holtsclaw, M. Cooper, and W. Dugan A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain J. Pain Symptom Manage. 23 2002 526 532
104. S.D. Passik, R.M. Navari, S.H. Jung, C. Nagy, J. Vinson, K.L. Kirsh, and P. Loehrer A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study Cancer Invest. 22 2004 383 388
105. G.W. Pasternak Preclinical pharmacology and opioid combinations Pain Med. 13 2012 S4 11
106. J.P. Patel, R. Sengupta, G. Bardi, M.Z. Khan, A. Mullen-Przeworski, and O. Meucci Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO J. Neurovirol. 12 2006 492 500
107. R.M. Pinder, R.N. Brogden, P.R. Sawyer, T.M. Speight, and G.S. Aver Metoclopramide: a review of its pharmacological properties and clinical use Drugs 12 1976 81 131
108. P. Popper, R. Cristobal, and P.A. Wackym Expression and distribution of mu opioid receptors in the inner ear of the rat Neuroscience 129 2004 225 233
109. R.K. Portenoy, J.T. Farrar, M.M. Backonja, C.S. Cleeland, K. Yang, M. Friedman, S.V. Colucci, and P. Richards Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study Clin. J. Pain 23 2007 287 299
110. G.D. Pratt, N.G. Bowery, G.J. Kilpatrick, R.A. Leslie, N.M. Barnes, R.J. Naylor, B.J. Jones, D.R. Nelson, J.M. Palacids, P. Slater, and D.J.M. Reynolds Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain Trends Pharmacol. Sci. 11 1990 135 137
111. E. Prommer Olanzapine: palliative medicine update Am. J. Hosp. Palliat. Care 30 2013 75 82
112. H. Quaynor, and J.C. Raeder Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies Acta Anaesthesiol. Scand. 46 2002 109 113
113. K.M. Raehal, J.J. Lowery, C.M. Bhamidipati, R.M. Paolino, J.R. Blair, D. Wang, W. Sadée, and E.J. Bilsky In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice J. Pharmacol. Exp. Ther. 313 2005 1150 1162
114. A.P. Ray, S. Chebolu, and N.A. Darmani Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva) Pharmacol. Biochem. Behav. 94 2009 211 218
115. A.P. Ray, S. Chebolu, J. Ramirez, and N.A. Darmani Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting Behav. Neurosci. 123 2009 701 706
116. G.W. Roberts, T.B. Bekker, H.H. Carlsen, C.H. Moffatt, P.J. Slattery, and A.F. McClure Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner Anesth. Analg. 101 2005 1343 1348
117. C. Rojas, Y. Li, J. Zhang, M. Stathis, J. Alt, A.G. Thomas, S. Cantoreggi, S. Sebastiani, C. Pietra, and B.S. Slusher The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo J. Pharmacol. Exp. Ther. 335 2010 362 368
118. C. Rojas, A.G. Thomas, J. Alt, M. Stathis, J. Zhang, E.B. Rubenstein, S. Sebastiani, S. Cantoreggi, and B.S. Slusher Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function Eur. J. Pharmacol. 626 2010 193 199
119. J.R. Ross, D. Rutter, K. Welsh, S.P. Joel, K. Goller, A.U. Wells, R. Du Bois, and J. Riley Clinical response to morphine in cancer patients and genetic variation in candidate genes Pharmacogenomics J. 5 2005 324 336
120. G.C. Rossi, G.P. Brown, L. Leventhal, K. Yang, and G.W. Pasternak Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia Neurosci. Lett. 216 1996 1 4
121. J.A. Rudd, and N.J. Naylor Morphine-induced emesis in ferret A.J. Bianchi, L. Grolot, A.D. Miller, G.L. King, Mechanisms and Control of Emesis vol. 223 1992 Colloque INSERM: John Libboy Eurotext Ltd. 351
122. W. Sadée, D. Wang, and E.J. Bilsky Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities Life Sci. 76 2005 1427 1437
123. R. Saito, H. Ariumi, H. Kubota, S. Nago, K. Honda, Y. Takano, and H. Kamiya The role of tachykinin NK-1 receptors in emetic action in the area postrema of ferrets Nihon Yakurigaku Zasshi 114 1999 209P 214P (Japanese)
124. M. Shiokawa, M. Narita, A. Nakamura, K. Kurokawa, T. Inoue, and T. Suzuki Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis Eur. J. Pharmacol. 570 2007 108 110
125. A.T. Sia, Y. Lim, E.C. Lim, R.W. Goh, H.Y. Law, R. Landau, Y.Y. Teo, and E.C. Tan A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia Anesthesiology 109 2008 520 526
126. P.M. Simpson, J.C. Bendall, and P.M. Middleton Review article: prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systemic review and meta-analysis of randomized controlled trials Emerg. Med. Australas. 23 2011 452 457
127. S. Sirohi, S.V. Dighe, P.A. Madia, and B.C. Yoburn The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity J. Pharmacol. Exp. Ther. 330 2009 513 519
128. C. Skarke, J. Darimont, H. Schmidt, G. Geisslinher, and J. Lotsch Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers Clin. Pharmacol. Ther. 73 2003 107 121
129. F. Skorpen, E.A. Laugsand, P. Klepstad, and S. Kaasa Variable response to opioid treatment: any genetic predictors within sight? Palliat. Med. 22 2008 310 327
130. H.S. Smith A receptor-based paradigm of nausea and vomiting J. Cancer Pain Symptom Palliat. 1 2005 11 23
131. H.S. Smith Balancing hedonic tone J. Cancer Pain Symptom Palliat. 2 2006 35 37
132. H.S. Smith Variations in opioid responsiveness Pain Physician 11 2008 237 248
133. H.S. Smith Combination opioid analgesics Pain Physician 11 2008 201 214
134. H.S. Smith Opioid metabolism Mayo Clin. Proc. 84 2009 613 624
135. H.S. Smith, L.R. Cox, and B.R. Smith Dopamine receptor antagonists Ann. Palliat. Med. 1 2012 137 142
136. H.S. Smith, J.M. Smith, and P. Seidner Opioid-induced nausea and vomiting Ann. Palliat. Med. 1 2012 121 129
137. C. Sternini, S. Patierno, I.S. Selmer, and A. Kirchgessner The opioid system in the gastrointestinal tract Neurogastroenterol. Motil. 16 2004 3 16
138. P. Tarkkila, K. Torn, M. Tuominen, and L. Lindgren Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine Acta Anaesthesiol. Scand. 39 1995 983 986
139. F.D. Tattersall, W. Rycroft, B. Francis, D. Pearce, K. Merchant, A.M. MacLeod, T. Ladduwahetty, L. Keown, C. Swain, R. Baker, M. Cascieri, E. Ber, J. Metzger, D.E. MacIntyre, R.G. Hill, and R.J. Hargreaves Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets Neuropharmacology 35 1996 1121 1129
140. J. Thomas Opioid-induced bowel dysfunction J. Pain Symptom Manage. 35 2008 103 113
141. P.I. Thompson, S. Bingham, P.L.R. Andrews, N. Patel, S.P. Joel, and M.L. Slevin Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret Br. J. Pharmacol. 106 1992 3 8
142. M.R. Tramer, and B. Walder Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review Anesth. Analg. 88 1999 1354 1361
143. D.D. Truong Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease Clin. Interv. Aging 4 2009 109 113
144. T.M. Tzschentke, T. Christoph, B. Kögel, K. Schiene, H.H. Hennies, W. Englberger, M. Haurand, U. Jahnel, T.I. Cremers, E. Friderichs, and J. De Vry (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties J. Pharmacol. Exp. Ther. 323 2007 265 276
145. T.M. Tzschentke, J. De Vry, R. Terlinden, H.-H. Hennies, C. Lange, W. Strassburger, M. Haurand, J. Kolb, J. Schneider, H. Buschmann, M. Finkam, U. Jahnel, and E. Friedrichs Tapentadol HCl Drugs Future 31 2006 1053 1061
146. K. Verebey The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics NIDA Res. Monogr. 28 1981 147 158
147. G. Vorsanger, J. Xiang, D. Biondi, D. Upmalis, J. Delfgaauw, R. Allard, and B. Moskovitz Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients Pain Res. Manag. 16 2011 245 251
148. J. Wallenborn, G. Gelbrich, D. Bulst, K. Behrends, H. Wallenborn, A. Rohrbach, U. Krause, T. Kühnast, M. Wiegel, and D. Olthoff Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomized double blind multicentre trial BMJ 333 2006 324
149. C. Walter, and J. Lotsch Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment Pain 146 2009 270 275
150. Q. Wan, S.D. Douglas, X. Wang, D.L. Kolson, L.A. O'Donnell, and W.Z. Ho Morphine upregulates functional expression of neurokinin-1 receptor in neurons J. Neurosci. Res. 84 2006 1588 1596
151. D. Wang, K.M. Raehal, E.J. Bilsky, and W. Sadée Inverse agonists and neutral antagonists at mu opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence J. Neurochem. 77 2001 1590 1600
152. D. Wang, K.M. Raehal, E.T. Lin, J.J. Lowery, B.L. Kieffer, E.J. Bilsky, and W. Sadée Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence J. Pharmacol. Exp. Ther. 308 2004 512 520
153. X. Wang, O. Dergacheva, H. Kamendi, C. Gorini, and D. Mendelowitz 5-Hydroxytryptamine 1A/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function Hypertension 50 2007 368 376
154. J.W. Watson, S.F. Gonsalves, A.A. Fossa, S. McLean, T. Seeger, S. Obach, and P.L. Andrews The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor Br. J. Pharmacol. 115 1995 84 94
155. L. Webster Efficacy and safety of dual-opioid therapy in acute pain Pain Med. 13 2012 S12 20
156. N. Weigert, A. Schaffler, J. Reichenberger, S. Madaus, M. Classen, and V. Schusdziarra Effect of endogenous opioids on vagally induced release of gastrin, somatostatin and bombesin-like immunoreactivity from the perfused rat stomach Regul. Pept. 55 1995 207 215
157. J.E. Wild, S. Grond, B. Kuperwasser, J. Gilbert, B. McCann, B. Lange, A. Steup, T. Häufel, M.S. Etropolski, C. Rauschkolb, and R. Lange Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain Pain Pract. 10 2010 416 427
158. S. Wirz, H.C. Wartenberg, and J. Nadstawek Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on caner pain Support. Care Cancer 16 2008 999 1009
159. B.G. Wolff, J.L. Weese, K.A. Ludwig, C.P. Delaney, M.J. Stamos, F. Michelassi, W. Du, and L. Techner Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection J. Am. Coll. Surg. 204 4 2007 609 616
160. X.S. Xu, M. Etropolski, D. Upmalis, A. Okamoto, R. Lin, and P. Nandy Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR Pharm. Res. 29 2012 2555 2564
161. J. Yancey-Wrona, B. Dallaire, E. Bilsky, B. Bath, J. Burkart, L. Webster, D. Magiera, X. Yang, M. Phelps, and W. Sadée 6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study Pain Med. 12 2011 1727 1737
162. B.J. Yates, A.D. Miller, and J.B. Lucot Physiological basis and pharmacology of motion sickness: an update Brain Res. Bull. 47 1998 395 406
163. J. Yip, and L.A. Chahl Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P Neuroscience 94 1999 663 673
164. K. Yokotani, and Y. Osumi Involvement of mu-receptor in endogenous opioid peptide-mediated inhibition of acetylcholine release from the rat stomach Jpn. J. Pharmacol. 78 1998 93 95
165. M. Yoshioka, Y. Goda, T. Ikeda, H. Togashi, T. Ushiki, and H. Saito Involvement of 5-HT3 receptors in the initiation of pharyngeal reflex Am. J. Physiol. 266 1994 R1652 1658
166. C.S. Yuan, and J.F. Foss Gastric effects of methylnaltrexone on μ, β, and δ opioid agonists induced brainstem unitary responses Neuropharmacology 38 1999 425 432
167. W. Zhang, J.J. Yuan, Q.C. Kan, L.R. Zhang, Y.Z. Chang, and Z.Y. Wang Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia Minerva Anestesiol. 77 2011 33 39
168. S.T. Zwisler, T.P. Enggaard, L. Noehr-Jensen, S. Mikkelsen, C. Verstuyft, L. Becquemont, S.H. Sindrup, and K. Brosen The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes Fundam. Clin. Pharmacol. 24 2010 517 524